Related Experiment Video

Updated: May 1, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K

Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport

M A Abdul-Ghani1, R A DeFronzo

  • 1Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Journal of Internal Medicine
|April 3, 2014
PubMed

Insights

New therapies targeting sodium-glucose cotransporter 2 (SGLT2) inhibitors offer effective glucose control for type 2 diabetes mellitus (T2DM). These agents work independently of insulin, addressing key metabolic issues and overcoming limitations of existing treatments.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Maintaining normal blood glucose levels (normoglycaemia) is crucial for preventing diabetic complications and addressing insulin resistance and beta-cell dysfunction in type 2 diabetes mellitus (T2DM).
  • Progressive beta-cell failure and side effects like hypoglycemia and weight gain from current antidiabetic drugs hinder optimal glycemic control in T2DM patients.
  • Novel therapeutic strategies are essential for effective glucose management in T2DM.

Purpose of the Study:

  • To review the mechanism of action, efficacy, and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors, a new class of antidiabetic agents.

Main Methods:

  • Review of available data on SGLT2 inhibitors.
  • Analysis of their unique mechanism of action.
  • Evaluation of efficacy and safety profiles.

Main Results:

  • SGLT2 inhibitors promote glucosuria, effectively lowering plasma glucose concentrations.
  • Their insulin-independent mechanism of action makes them effective across all disease stages.
  • These agents can be safely combined with other antidiabetic medications.

Conclusions:

  • SGLT2 inhibitors represent a promising novel therapeutic option for T2DM management.
  • Their distinct mechanism offers advantages over existing treatments, addressing key challenges in glycemic control.
  • Further data on efficacy and safety support their role in T2DM therapy.
Keywords:
SGLT2 inhibitionkidneysodium-glucose cotransporttype 2 diabetes

More Related Videos

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas04:41

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

1.2K
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

11.7K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
953
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
12.8K
Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
122.9K